中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
26期
18-19
,共2页
慢性乙型肝炎%恩替卡韦%HBV基因型%HBV DNA
慢性乙型肝炎%恩替卡韋%HBV基因型%HBV DNA
만성을형간염%은체잡위%HBV기인형%HBV DNA
Hepatitis B virus%Entecavir%Genotype%HBV DNA
目的：探讨HBV基因型与恩替卡韦治疗后病毒学应答的关系。方法：56例入选CHB患者采用线性探针反向杂交法（INNO-LiPA）检测HBV基因型，给予恩替卡韦（0.5 mg/d）抗病毒治疗48周。比较治疗前后ALT复常率、HBeAg血清转换率和HBV DNA载量的变化。结果：56例入选患者进行了HBV基因型检测，30例为B型，26例为C型。恩替卡韦治疗48周后，两组基因型感染者ALT复常率、HBeAg血清转换率和HBV DNA载量变化差异无统计学意义（P>0.05）。结论：恩替卡韦的抗HBV疗效与感染HBV基因型B型或C型无关。
目的：探討HBV基因型與恩替卡韋治療後病毒學應答的關繫。方法：56例入選CHB患者採用線性探針反嚮雜交法（INNO-LiPA）檢測HBV基因型，給予恩替卡韋（0.5 mg/d）抗病毒治療48週。比較治療前後ALT複常率、HBeAg血清轉換率和HBV DNA載量的變化。結果：56例入選患者進行瞭HBV基因型檢測，30例為B型，26例為C型。恩替卡韋治療48週後，兩組基因型感染者ALT複常率、HBeAg血清轉換率和HBV DNA載量變化差異無統計學意義（P>0.05）。結論：恩替卡韋的抗HBV療效與感染HBV基因型B型或C型無關。
목적：탐토HBV기인형여은체잡위치료후병독학응답적관계。방법：56례입선CHB환자채용선성탐침반향잡교법（INNO-LiPA）검측HBV기인형，급여은체잡위（0.5 mg/d）항병독치료48주。비교치료전후ALT복상솔、HBeAg혈청전환솔화HBV DNA재량적변화。결과：56례입선환자진행료HBV기인형검측，30례위B형，26례위C형。은체잡위치료48주후，량조기인형감염자ALT복상솔、HBeAg혈청전환솔화HBV DNA재량변화차이무통계학의의（P>0.05）。결론：은체잡위적항HBV료효여감염HBV기인형B형혹C형무관。
Objective:To study the association between HBV genotype and the virologic response in patients with entecavir treatment. Method:The HBV genotypes of 56 patients with chronic hepatitis B(CHB)were detected by INNO-LiPA assay.All the patients were given entecavir (0.5 mg/d)treatment for 48 weeks.The changes of ALT level,HBeAg status and serum HBV DNA level were observed before and after treatment in all patients.Result:Among 56 CHB cases,30 cases were genotype B,26 were genotype C.There were no significant differences in the changes of ALT normalization,HBeAg seroconversion and serum HBV DNA levels between the patients infected HBV genotype B or C(P>0.05). Conclusion:The study shows that the virologic response to entecavir treatment is not correlated with HBV genotype.
